- Home
- ACIC vs MLYS Comparison
ACIC vs MLYS Comparison
Compare ACIC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- MLYS
- Stock Information
- Founded
- ACIC 1999
- MLYS 2019
- Country
- ACIC United States
- MLYS United States
- Employees
- ACIC N/A
- MLYS N/A
- Industry
- ACIC Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- MLYS Health Care
- Exchange
- ACIC Nasdaq
- MLYS Nasdaq
- Market Cap
- ACIC 588.1M
- MLYS 526.1M
- IPO Year
- ACIC N/A
- MLYS 2023
- Fundamental
- Price
- ACIC $11.92
- MLYS $10.21
- Analyst Decision
- ACIC Buy
- MLYS Strong Buy
- Analyst Count
- ACIC 1
- MLYS 2
- Target Price
- ACIC $16.00
- MLYS $30.00
- AVG Volume (30 Days)
- ACIC 156.1K
- MLYS 263.5K
- Earning Date
- ACIC 02-27-2025
- MLYS 03-20-2025
- Dividend Yield
- ACIC 4.18%
- MLYS N/A
- EPS Growth
- ACIC N/A
- MLYS N/A
- EPS
- ACIC 1.76
- MLYS N/A
- Revenue
- ACIC $290,784,000.00
- MLYS N/A
- Revenue This Year
- ACIC N/A
- MLYS N/A
- Revenue Next Year
- ACIC $12.68
- MLYS N/A
- P/E Ratio
- ACIC $6.77
- MLYS N/A
- Revenue Growth
- ACIC 1.02
- MLYS N/A
- 52 Week Low
- ACIC $8.82
- MLYS $8.58
- 52 Week High
- ACIC $15.08
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- ACIC 38.97
- MLYS 44.53
- Support Level
- ACIC $11.81
- MLYS $9.57
- Resistance Level
- ACIC $12.66
- MLYS $10.79
- Average True Range (ATR)
- ACIC 0.32
- MLYS 0.64
- MACD
- ACIC 0.00
- MLYS 0.11
- Stochastic Oscillator
- ACIC 10.38
- MLYS 63.98
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.